



February 25, 2025  
JCR Pharmaceuticals Co., Ltd.

### Notice Concerning the Start of Construction of a New Drug Product Plant

**Hyogo, Japan – February 25, 2025 – [JCR Pharmaceuticals Co., Ltd.](#)** (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that the Company has started construction of a new plant for drug product filling and finishing (“this new plant”) in the Kobe Science Park Center.

At the Kobe Science Park Center, construction of an Active Pharmaceutical Ingredient (API) plant was completed in November 2022 and the plant is now in operation. JCR, in cooperation with the adjacent API plant, will construct this new plant with the aid of subsidies from “Project for Establishing Biopharmaceutical Manufacturing Sites to Strengthen Vaccine Production” selected by the Ministry of Economy, Trade and Industry (METI). The objective is establishment of an integrated plant system for contract manufacturing of vaccines in case of a pandemic emergency.

JCR is a full-fledged biopharma with capabilities from research and development to manufacturing and is currently developing multiple protein therapy products for the treatment of lysosomal storage disorders applying its proprietary blood-brain-barrier (BBB) penetration technology, J-Brain Cargo®. The construction of this new plant will allow JCR to enhance its quality standards for global development and increase fill and finish capacities in case the facilities are not utilized for vaccine production and confectioning in case of a pandemic emergency.

The impact of this matter on our consolidated financial results for the current fiscal year (ending March 31, 2025) is expected to be minor.

\* The following two press releases have been disclosed in connection with this matter.

"Notice of Selection as METI 'Project for Establishing Biopharmaceutical Manufacturing Sites to Strengthen Vaccine Production' dated October 3, 2022  
<https://ssl4.eir-parts.net/doc/4552/tdnet/2186623/00.pdf>

"Notice of Construction of a New Plant for Drug Product Filling and Finishing" dated October 26, 2022.  
<https://ssl4.eir-parts.net/doc/4552/tdnet/2192404/00.pdf>

#### Outline of this new plant

Name	New Drug Product Plant (tentative)
Location	7-3-10, Ibukidai Higashimachi, Nishi-ku, Kobe (Kobe Science Park Center)
Scale	Formulation building 3 stories above ground Office building 3 stories above ground Automated warehouse building 3 stories above ground
Site area	27, 557 m <sup>2</sup>
Building area	5,060 m <sup>2</sup>
Total floor area	14,775 m <sup>2</sup>

Construction period February 2025 - September 2026 (planned)  
Total construction cost Approx. 25 billion yen  
Plans to utilize subsidies from “Project for Establishing Biopharmaceutical Manufacturing Sites to Strengthen Vaccine Production”

Completion drawing



Contact:  
Investors & Media:  
JCR Pharmaceuticals Co., Ltd.  
Corporate Communications  
[ir-info@jp.jcrpharm.com](mailto:ir-info@jp.jcrpharm.com)

###